CoChat
Sign Up
Cited by 774Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Meta-Analysis: Pharmacologic Treatment of Obesity

Li, Zhaoping, Maglione, Margaret, Tu, Wenli, Mojica, Walter, Arterburn, David, Shugarman, Lisa R., Hilton, Lara, Suttorp, Marika, Solomon, Vanessa, Shekelle, Paul G., Morton, Sally C.·2005·Annals of Internal Medicine
DOI 10.7326/0003-4819-142-7-200504050-00012
Open this paper in CoChat — free account

Abstract

BACKGROUND: In response to the increase in obesity, pharmacologic treatments for weight loss have become more numerous and more commonly used. PURPOSE: To assess the efficacy and safety of weight loss medications approved by the U.S. Food and Drug Administration and other medications that have been used for weight loss. DATA SOURCES: Electronic databases, experts in the field, and unpublished information. STUDY SELECTION: Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified. The authors assessed in detail 50 studies of orlistat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamide. Meta-analysis was performed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narratively. DATA EXTRACTION: The authors abstracted information about study design, intervention, co-interventions, population, outcomes, and methodologic quality, as well as weight loss and adverse events from controlled trials of medication. DATA SYNTHESIS: All pooled weight loss values are reported relative to placebo. A meta-analysis of sibutramine reported a mean difference in weight loss of 4.45 kg (95% CI, 3.62 to 5.29 kg) at 12 months. In the meta-analysis of orlistat, the estimate of the mean weight loss for orlistat-treated patients was 2.89 kg (CI, 2.27 to 3.51 kg) at 12 months. A recent meta-analysis of phentermine and diethylpropion reported pooled mean differences in weight loss at 6 months of 3.6 kg (CI, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (CI, -1.6 to 11.5 kg) for diethylpropion-treated patients. Weight loss in fluoxetine studies ranged from 14.5 kg of weight lost to 0.4 kg of weight gained at 12 or more months. For bupropion, 2.77 kg (CI, 1.1 to 4.5 kg) of weight was lost at 6 to 12 months. Weight loss due to topiramate at 6 months was 6.5% (CI, 4.8% to 8.3%) of pretreatment weight. With one exception, long-term studies of health outcomes were lacking. Significant side effects that varied by drug were reported. LIMITATIONS: Publication bias may exist despite a comprehensive search and despite the lack of statistical evidence for the existence of bias. Evidence of heterogeneity was observed for all meta-analyses. CONCLUSIONS: Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along with recommendations for diet. Sibutramine and orlistat are the 2 most-studied drugs.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-142-7-200504050-00012

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 83 references

Research works printed but not linked: 14

  1. 10.1001/jama.1994.03520030047027 · DOI
  2. Katzmarzyk PT, 2002, CMAJ, 166, 1039
  3. 1998, Obes Res, 6, 51S
  4. Goldstein DJ, 1992, Int J Obes Relat Metab Disord, 16, 397
  5. Hauner H, 2000, Int J Obes Relat Metab Disord, 24, S100
  6. Smith IG, 2001, J Fam Pract, 50, 505
  7. Deerochanawong C, 2001, Diabetes, 50, A433
  8. Naumov VG, 2002, Ter Arkh, 74, 47
  9. Micic D, 1999, Med Pregl, 52, 323
  10. Kim I, 1988, J Okla State Med Assoc, 81, 395
  11. Goldstein DJ, 1994, Int J Obes Relat Metab Disord, 18, 129
  12. Mendoza Espejo R, 1995, Aten Primaria, 16, 364
  13. Gray DS, 1992, Int J Obes Relat Metab Disord, 16, 193
  14. Anderson JW, 2001, Diabetes, 50, A21

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., & Morton, S. C.
Affiliations
United States Department of Veterans Affairs (US)
ORCID
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
2005-04-05
Volume
142
Issue
7
Pages
532-546
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-142-7-200504050-00012
OpenAlex
W2136335834
Cited by
774
References
83
Citations by year
2026: 7 · 2025: 7 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 24 · 2020: 8 · 2019: 13 · 2018: 19 · 2017: 22 · 2016: 24 · 2015: 46 · 2014: 37 · 2013: 62 · 2012: 61
FWCI
8.97
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, anti-obesity drugs, sibutramine, orlistat, phentermine, diethylpropion, fluoxetine, bupropion, topiramate, weight loss efficacy, adverse events, long-term health effects, appetite suppressants, appetite stimulants
MeSH terms
Adult, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review